Zymeworks Inc.

Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases.

[Zymeworks Inc. @ZymeworksInc]

We’re looking forward to participating in the Jefferies Global Healthcare Conference in New York this week.

Management will take part in a fireside chat on June 3 at 8:45 a.m. ET to discuss our continued progress advancing innovative therapeutics for patients with difficult-to-treat cancers and other serious diseases.

Join the webcast here: https://t.co/afaioqllhA

[Zymeworks Inc. @ZymeworksInc]

Happy #PrideMonth!

This month, we recognize and celebrate the history and contributions of the #LGBTQ+ community and the ongoing pursuit of equality, inclusion, and acceptance.

At Zymeworks, we believe that different perspectives, experiences, identities, and backgrounds make us stronger. We are committed to fostering a culture where employees feel supported, valued, and empowered to bring their authentic selves to work.

We’re proud to celebrate Pride and amplify the voices of the LGBTQ+ community across the life sciences industry.

#Pride2026 #Biotech

[Zymeworks Inc. @ZymeworksInc]

This Memorial Day, we honor and remember the courageous individuals who gave their lives in service to their country.

Their sacrifice serves as a lasting reminder of the freedoms we value and the responsibility we share to uphold them. At Zymeworks, we are grateful to those who served and to the families who continue to carry their legacy forward.

Wishing everyone a meaningful Memorial Day.

[Zymeworks Inc. @ZymeworksInc]

We’re looking forward to participating in the @Stifel Virtual Targeted Oncology Forum this week. Management will take part in a fireside chat on May 20 at 9:00 am ET - join the webcast: https://t.co/C3HbhLntnO

[Zymeworks Inc. @ZymeworksInc]

We just wrapped a great week at PEGS Boston and appreciated the opportunity to connect with so many colleagues advancing the field of antibody engineering.

Our team was proud to share some of our latest work — thank you to everyone who stopped by to connect! If you missed the presentations or want to revisit the data, access the presentations here: https://t.co/mvgXEHS8AQ

Curious about our ADC and multispecific programs? Learn more at https://t.co/4GU86zySyS

#ADC #antibodydrugconjugate #trispecifics #PEGSBoston

[Zymeworks Inc. @ZymeworksInc]

We’re pleased to welcome Paul Schneider as our new General Counsel.

With more than 20 years of legal experience advising on strategic transactions across the life sciences sector – including in-licensing, out-licensing, collaborations, and M&A – his combination of legal expertise and scientific background will be valuable as we continue advancing our pipeline and business.

We also extend our sincere thanks to our outgoing General Counsel, Daniel Dex, for his contributions over the past several years. Since joining Zymeworks in 2017, he has played an important role in helping shape the company and has been a trusted advisor to leadership. We are grateful for his impact and wish him all the best in his next chapter.

[Zymeworks Inc. @ZymeworksInc]

Management are pleased to present at the following investors conferences in May and June - learn more: https://t.co/GVhJethoz9

[Zymeworks Inc. @ZymeworksInc]

We’re heading to the 2026 Respiratory Innovation Summit in Orlando, FL (May 15–16), hosted by the American Thoracic Society!

Our team will present “ZW1528: IL-4Rα x IL-33 Bispecific Antibody for Treatment of COPD” (poster no. 117), showcasing our work on our novel IL-4Rɑ x IL-33 bispecific molecule targeting respiratory inflammation, including mixed-type chronic obstructive pulmonary disease (COPD). Stop by to connect with our team and learn more about our AIID programs.

Learn more: https://t.co/wMyvdRBvGo

#RespiratoryInnovation #COPD #Bispecific #AIID

[American Thoracic Society (ATS) @atscommunity]

⏰Don't miss out! The ATS 2026 Respiratory Innovation Summit will unite the innovators, investors, clinicians and advocacy groups who are leading the charge to create powerful new treatments and tools.

ATS Thanks Boehringer Ingelheim Pharmaceuticals, Inc., Insmed Incorporated, Genentech, GSK, Catalent, Lovelace Biomedical, Ritedose Corp., SMSBiotech, and Vitalograph for their generous support of the ATS 2026 Respiratory Innovation Summit.

Get your ticket today - space is limited! https://t.co/2qAjXqMHCb

[Zymeworks Inc. @ZymeworksInc]

Ovarian cancer remains one of the most challenging cancers to diagnose and treat — with many patients facing limited options, especially in later stages.

Advancing new approaches is critical to changing this reality.

On World Ovarian Cancer Day, we recognize the urgency of continued research and innovation — and the importance of working toward better outcomes for patients.

#WorldOvarianCancerDay #OvarianCancer #OncologyResearch #OvarianCancerAwareness

[Zymeworks Inc. @ZymeworksInc]

Today we reported our Q1 2026 financial results. Join our management team for a live webcast at 4:30 pm ET as we review business updates and progress across our pipeline.

Join the webcast: https://t.co/uJfwAt6JZ9

Read the press release: https://t.co/HREC67XKVk

[Zymeworks Inc. @ZymeworksInc]

We’re heading to PEGS Boston next week! Join us for:

Panel

Advancing Multispecific Antibodies and Combination Therapies to the Clinic
May 13 | 2:40 pm ET
Presenter: Dr. Nina E. Weisser

Posters

Uniting Discovery Strategy and Engineering for the Best-in-Class Antibodies for ADC
May 12 | 4:00 pm ET
May 13 | 6:20 pm ET
Presenter: Dr. Germanna Righetto

TriTCE Co-Stim: A Differentiated T Cell Engager Platform with Conditional cis CD28 Co-Stimulation
May 14 | 8:50 am ET
Presenter: Dr. Genevieve Desjardins

If you’re attending, we’d welcome the opportunity to connect. Learn more about our ADC and multispecific programs: https://t.co/Ex5qbfjgOe

#PEGSBoston #ADC #Multispecifics #Biotech

[Zymeworks Inc. @ZymeworksInc]

May is National Cancer Research Month.

Our mission is rooted in advancing science that makes a meaningful difference for patients with difficult to treat cancers. Through our fully integrated, in-house R&D engine, we’re working to translate innovative science into potential new treatment options.

To the researchers, clinicians, and patients driving progress forward — we’re proud to be part of this effort.

Learn more: https://t.co/4GU86zySyS

#CancerResearch #Biotech #Innovation #Oncology

[Zymeworks Inc. @ZymeworksInc]

May is Mental Health Awareness Month — a reminder that taking care of our mental well-being is just as important as physical health.
At Zymeworks, we’re committed to fostering a workplace where our people feel supported, balanced, and empowered to do their best work — for themselves and for the patients we serve. Our Health & Wellness benefits programs, such as ZymeLife and Flexible Time-off, are designed to support employees in prioritizing their well-being. Learn more: https://t.co/EiESZCZ4V8

#MentalHealthAwarenessMonth #MentalHealthAtWork

[Zymeworks Inc. @ZymeworksInc]

Congratulations to the team at @BeOneMedicines on this important milestone! The FDA’s Priority Review highlights the potential of this combination approach in the first-line treatment of HER2-positive gastroesophageal adenocarcinoma—an area with significant unmet need for patients.

#GEA #oncology

[BeOne Medicines @BeOneMedicines]

#News for #Investors and #Media: BeOne Medicines is pleased to announce the FDA has granted Priority Review for our PD-1 inhibitor in combination with a HER2-directed antibody and chemotherapy for the first-line treatment of HER2+ gastroesophageal adenocarcinoma.

Read the full press release here: https://t.co/754fnvWGCv

#Oncology #CancerResearch #GEA

[Zymeworks Inc. @ZymeworksInc]

We’re pleased to share news from our partner, @JazzPharma! Backed by Phase 3 data, this sBLA highlights an important step forward to redefine care for people living with HER2+ gastroesophageal adenocarcinoma, where significant unmet need remains.

[Jazz Pharmaceuticals @JazzPharma]

#News for U.S. media and investors: Today, the U.S. FDA accepted and granted Priority Review for the supplemental Biologic License Application (sBLA) for our potential treatment for HER2+ unresectable locally advanced or metastatic GEA. Learn more: https://t.co/lvDZkjfqSD

[Zymeworks Inc. @ZymeworksInc]

AACR 2026 was amazing! A week full of science, collaboration, and connection — and a great reminder of the collective effort driving progress in cancer research. We couldn't be more proud of our team for their hard work that goes into the science behind our programs and leading up to our presentations.

Explore all that Zymeworks shared at AACR: https://t.co/FDopnaA5HM

#AACR26 #Oncology

[Zymeworks Inc. @ZymeworksInc]

Today we celebrate Earth Day and reaffirm our commitment to taking actions to protect our planet and environment. As we work to develop novel medicines for patients with difficult-to-treat cancers and other serious diseases, we recognize the importance of minimizing our environmental footprint and are actively working towards sustainable solutions. Read our 2025 ESG report: https://t.co/tZ75f0qATT

[Zymeworks Inc. @ZymeworksInc]

On National Administrative Professionals Day, we extend our deepest thanks to our administrative team at Zymeworks—your professionalism, care, and behind-the-scenes leadership are essential to advancing our mission.

#collaboration #AdministrativeProfessionalsDay

[Zymeworks Inc. @ZymeworksInc]

Today we presented new Phase 1 Data for our folate receptor alpha-targeting antibody-drug conjugate at #AACR26. The ADC demonstrates encouraging anti-tumor activity in heavily pretreated ovarian and endometrial cancers, regardless of FRα expression.

“We are highly encouraged by the initial clinical data for ZW191, which reinforce the strength of our ADC platform and its ability to generate differentiated therapeutics. The breadth and durability of responses, along with activity across varying levels of FRα expression, support further development of ZW191 as a potential best-in-class agent for patients with ovarian and endometrial cancers.” - Dr. Sabeen Mekan, SVP and Chief Medical Officer.

View the presentation: https://t.co/DbDY5YRst2

Read our press release: https://t.co/Q7hoFzpXKa